|
|
|
|
|
NAD+APO866 is a new chemical entity representing a novel mechanism of action for an anti-cancer drug. APO866 was discovered during a search for compounds that did not exhibit acute cytotoxicity and was initially found to induce a "delayed cell death" by apoptosis. The mechanism of action was determined to be the inhibition of NAPRT, an enzyme involved in the biosynthesis of NAD+ from niacinamide (vitamin B3), eventually leading to induction of apoptotic cell death. APO866 therefore preferentially affects cells and tissues with a high NAD turnover. Such NAD-consuming reactions are high in tumor cells, which have a relatively unstable genome and are permanently undergoing poly-ADP ribosylation (PARP) dependent DNA repair. In addition, APO866 was found to possess anti-angiogenic properties, which may also be a consequence of the primary mechanism of action. As APO866 is not subject to commonly known MDR mechanisms, acts independently of cellular proliferation and is active on slow growing tumour cells, it represents a new therapeutic option for cancer patients who are no longer amenable to standard chemotherapy.Useful links :
Products and Projects
- APO866
|
|
|
About Us
Cancer